TrialBlood advances2024

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.

Armin Ghobadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.